Yilmaz Musa, Richard Samantha, Jabbour Elias
Department of Hematology and Oncology, Baylor College of Medicine, Houston, TX, USA.
Department of Leukemia, The University of Texas M. D. Anderson Cancer Center, Houston, TX, USA.
Ther Adv Hematol. 2015 Oct;6(5):253-61. doi: 10.1177/2040620715596715.
Antibody-drug conjugates (ADCs) are likely to make a significant contribution in the treatment of acute lymphoblastic leukemia (ALL) by combining the cytotoxicity of chemotherapy with the specificity of monoclonal antibodies. CD22, an endocytic receptor expressed by the majority of B cells, is an excellent target for ADCs. Inotuzumab ozogamicin (INO) is an ADC that consists of a cytotoxic moiety (derivative of calicheamicin) attached to a humanized monoclonal anti-CD22 antibody. As a single agent, INO, was shown to be effective with an objective response rate of 50% in the treatment of relapsed and refractory CD22 positive ALL patients. Clinical trials investigating the combination of INO with the conventional chemotherapies are ongoing. This review summarizes the clinical potential of INO in treatment of relapsed and refractory ALL, based on currently available data in the literature.
抗体药物偶联物（ADCs）通过将化疗的细胞毒性与单克隆抗体的特异性相结合，可能在急性淋巴细胞白血病（ALL）的治疗中发挥重要作用。CD22是大多数B细胞表达的一种内吞受体，是ADC的理想靶点。奥英妥珠单抗（INO）是一种ADC，由连接到人源化抗CD22单克隆抗体上的细胞毒性部分（刺孢霉素衍生物）组成。作为单一药物，INO在复发和难治性CD22阳性ALL患者的治疗中显示出有效性，客观缓解率为50%。正在进行研究INO与传统化疗联合使用的临床试验。本综述基于文献中目前可用的数据，总结了INO在复发和难治性ALL治疗中的临床潜力。
